Acetyl-CoA carboxylase 1 (ACC1), the rate-limiting enzyme in this process, has emerged as a target for treating acute myeloid leukemia, breast cancer, ovarian cancer, non-small cell lung cancer, and liver cancer [183, 184]. This evidence concerns the gene ACACA and ovarian cancer.